Shaffer J L, Kershaw A, Houston J B
Br J Clin Pharmacol. 1986 Apr;21(4):431-5. doi: 10.1111/j.1365-2125.1986.tb05218.x.
The pharmacokinetics of metronidazole were studied after oral and intravenous administration to seven patients with Crohn's disease and five patients with ulcerative colitis. The oral/intravenous availability ratio was 0.97 +/- 0.2 in the Crohn's patients and 0.90 +/- 0.1 in the colitics (mean +/- s.e. mean). Plasma clearance was 3.24 +/- 0.2 l h-1 and 4.1 +/- 0.5 l h-1, respectively. These differences were not statistically significant. Ten of the patients on long term sulphasalazine were studied to observe the effect of 2 weeks metronidazole therapy on plasma sulphapyridine concentration. The sulphapyridine concentration changed from 22.1 +/- 2.0 micrograms ml-1 to 15.95 +/- 4.5 micrograms ml-1 in the Crohn's patients and 26.0 +/- 6.0 micrograms ml-1 to 36.4 +/- 8.5 micrograms ml-1 in the colitis group, pre- and post-metronidazole. These differences were not statistically significant. These results suggest that metronidazole does not interfere with diazo-link splitting of sulphasalazine and that patients with Crohn's disease handle metronidazole in a similar manner to patients with colitis.
对7例克罗恩病患者和5例溃疡性结肠炎患者分别进行口服和静脉注射甲硝唑后的药代动力学研究。克罗恩病患者的口服/静脉给药可利用度比值为0.97±0.2，结肠炎患者为0.90±0.1（均值±标准误均值）。血浆清除率分别为3.24±0.2 l h⁻¹和4.1±0.5 l h⁻¹。这些差异无统计学意义。对10例长期服用柳氮磺胺吡啶的患者进行研究，观察甲硝唑治疗2周对血浆磺胺吡啶浓度的影响。在克罗恩病患者中，甲硝唑治疗前后，磺胺吡啶浓度从22.1±2.0微克/毫升变为15.95±4.5微克/毫升；在结肠炎组中，从26.0±6.0微克/毫升变为36.4±8.5微克/毫升。这些差异无统计学意义。这些结果表明，甲硝唑不干扰柳氮磺胺吡啶的重氮键裂解，且克罗恩病患者对甲硝唑的处理方式与结肠炎患者相似。
